Support online!Mashema is an upcoming semaglutide injection developed by Zydus Lifesciences. The medication belongs to a class of drugs known as GLP-1 receptor agonists, which are commonly used to treat type-2 diabetes and support weight management. Semaglutide works by mimicking the action of a natural hormone called glucagon-like peptide-1 (GLP-1). This hormone helps regulate blood sugar levels, slows stomach emptying, and reduces appetite, making it effective both for glycemic control and for reducing calorie intake.
Mashema is expected to be supplied in a multi-dose injection pen containing 15 mg of semaglutide in 3 mL of solution. The pen allows patients to select different weekly doses depending on their treatment stage. Because semaglutide is a long-acting medication, it is typically administered once per week.
How Mashema Is Dosed
Treatment with semaglutide generally follows a gradual dose-escalation schedule. Starting with a lower dose helps the body adjust and can reduce common side effects such as nausea.
A typical dosing schedule may include:
0.25 mg once weekly (Weeks 1–4)
This is the usual starting dose used to help the body adapt to the medication.0.5 mg once weekly (Weeks 5–8)
After four weeks, the dose is usually increased to improve blood sugar control.1 mg once weekly
Many patients remain at this dose for diabetes management if adequate results are achieved.1.7 mg once weekly
For patients using semaglutide for weight management, the dose may be gradually increased.2 mg or up to 2.4 mg once weekly
Higher maintenance doses may be used when stronger appetite suppression or metabolic control is needed, depending on medical guidance.
Patients typically inject Mashema subcutaneously, meaning the injection is placed under the skin. Common injection sites include the abdomen, thigh, or upper arm. The injection should be administered on the same day each week, although the day can be changed if at least 48 hours have passed since the last dose.
Important Considerations
Mashema is intended for individuals diagnosed with type-2 diabetes or those seeking medical treatment for chronic weight management. Like other semaglutide medications, it should be used alongside lifestyle measures such as a balanced diet and regular physical activity.
Because Mashema uses a multi-dose pen, the device allows patients to adjust the weekly dose without needing a new pen for each strength. This design can make treatment more convenient and may help simplify long-term therapy.
As with any prescription medication, dosing and treatment decisions should be made under the supervision of a qualified healthcare professional who can evaluate individual needs and monitor progress throughout the therapy.